Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)

The summary for the Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed): The purpose of this Notice of Funding Opportunity (NOFO) is to develop multi-organ automated microphysiological systems (MPS) for studying the effects of microgravity conditions on human body in low Earth orbit at the International Space Station National Laboratory (ISS-NL). This program will provide insights on human patho(physiology), especially aging-related functional decline and age-related diseases. The multi-organ MPS configuration will allow better modeling of the whole organism. Improved automation with extended longevity of MPS will facilitate longer experiments in space and the collection of more physiologically relevant data. The inclusion of samples representing the broad spectrum of diversity in the human population will allow for better modeling of aging progression and development of interventions.

Federal Grant Title:	Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-TR-24-025
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.350, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 18th, 2024
Original Application Deadline:	October 18th, 2024
Posted Date:	July 25th, 2024
Creation Date:	July 25th, 2024
Archive Date:	November 23rd, 2024
Total Program Funding:
Maximum Federal Grant Award:	$750,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 25th, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-025.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Clinical and Translational Science Award (UM1 Clinical Trial Optional); • Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) f...; • Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed); • Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...; • Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not...; • Limited Competition: Revision Applications to Advance Evidence-Based Research Related to P...; • A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for...; • Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for E...
More Grants from the National Institutes of Health: • Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not All...; • U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 C...; • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...; • Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional); • Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed)